I need to read through the filing carefully to extract the key financial data before writing the article. The filing is a 10-Q for USANA Health Sciences, Inc. for the quarterly period ended October 3, 2026, filed on November 12, 2026. The ticker is USNA on the New York Stock Exchange. However, I notice the filing content provided is primarily the cover page, table of contents, and the cautionary note regarding forward-looking statements. The actual financial statements and MD&A content appear to be cut off. Let me assess what substantive disclosure content is available. The substantive content I can confirm from the filing includes: the quarterly period (October 3, 2026), share count (18,488,751 as of November 6, 2026), auditor information (KPMG LLP, Salt Lake City, Utah, Firm ID 185), the company's status as an accelerated filer, and business description details from the forward-looking statements section including references to subsidiaries Hiya Health Products, LLC and Rise Wellness, Inc., and BabyCare Holdings, Ltd. The forward-looking statements section does contain substantive disclosure content exceeding 150 words, including business model disclosures, subsidiary names, and risk factor descriptions. Let me proceed with what is available.

USANA Health Sciences, Inc. filed its Form 10-Q for the quarterly period ended October 3, 2026, with the Securities and Exchange Commission on November 12, 2026, reporting 18,488,751 shares of common stock outstanding as of November 6, 2026.

Key Highlights

  • Share count: 18,488,751 shares of common stock, $0.001 par value, were outstanding as of November 6, 2026, according to the filing.
  • Filer status: The company indicated it is classified as an accelerated filer under Rule 12b-2 of the Exchange Act.
  • Auditor: KPMG LLP, based in Salt Lake City, Utah (Auditor Firm ID: 185), serves as the registrant's auditor, as disclosed on the cover page.
  • Business evolution: The filing discloses that the company has been evolving into "an omni-channel health and wellness company," with acquired direct-to-consumer businesses Hiya Health Products, LLC and Rise Wellness, Inc.
  • Core business trends: The filing states that the core direct sales business "has experienced a decline in net sales, net income and active Customers over the last few years."
  • China operations: The company operates its Core Nutritional business in China through its subsidiary BabyCare Holdings, Ltd., according to the filing.

USANA's Q3 2026 Filing: Omni-Channel Shift and Core Business Challenges

USANA Health Sciences, Inc. (NYSE:USNA), headquartered at 3838 West Parkway Blvd., Salt Lake City, Utah 84120, filed its quarterly report on Form 10-Q for the period ended October 3, 2026. The filing identifies 18,488,751 shares of common stock outstanding as of November 6, 2026, with a par value of $0.001 per share. The company holds Commission file number 001-35024 and is incorporated in Utah with I.R.S. Employer Identification No. 87-0500306.

According to the filing, the company's registered independent Brand Partners, whom it formerly referred to as "Associates," form the foundation of its Core Nutritional direct sales business model. The filing discloses that this core business "has experienced a decline in net sales, net income and active Customers over the last few years." Alongside this, the company describes its evolution into an omni-channel health and wellness company, citing reliance on its acquired subsidiaries, Hiya Health Products, LLC ("Hiya") and Rise Wellness, Inc. ("Rise"), to grow in direct-to-consumer, retail, and online marketplace channels.

The filing also identifies ongoing operational risks including the activities of the company's subsidiary BabyCare Holdings, Ltd., which manages operations in China, and notes regulatory considerations around direct selling, anti-pyramiding laws, data privacy regulations in China, and trade and export control frameworks. The cautionary language in the filing states that forward-looking statements "are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict," and the company notes it undertakes no obligation to publicly update any such statements. These characterizations are the company's own and are subject to its cautionary language as set forth in the filing.

What Was Disclosed

USANA Health Sciences filed a Form 10-Q for the quarter ended October 3, 2026, disclosing 18,488,751 shares outstanding, its accelerated filer status, auditor details, and business context including a stated multi-year decline in its core direct sales business and ongoing omni-channel expansion through two acquired subsidiaries.